These results proved again that lumbrokinase synergizes with bevacizumab or chemotherapeutics in antagonism to NSCLC progression by inactivating BPTF/VEGF and NF-κB/COX-2 signaling to inhibit the formation of tumor blood vessels and enhance the chemosensitivity of tumor cells. Here, BPTF is linked to non-small cell lung carcinoma.